Key result
Syncope shows no independent link to all-cause mortality in transthyretin amyloid cardiomyopathy.
Why the study?
The clinical characteristics, underlying causes, and outcomes of syncope in patients with transthyretin amyloid cardiomyopathy were not well defined.
Does syncope increase the risk of all-cause mortality in patients with transthyretin amyloid cardiomyopathy?
Population
128 patients with ATTR-CM across 7 hospitals in Galicia, Spain
Comparison
Patients with syncope vs patients without syncope
Design
Prospective multicentre registry cohort study
Follow-up
Median 520 days
Authors
Loading...
Syncope should not yet inform mortality risk stratification in ATTR-CM; leaves open association in larger prospective cohorts.
Cohort (n=128)
Yes
Does syncope increase the risk of all-cause mortality in patients with transthyretin amyloid cardiomyopathy?
Hazard Ratio: 1.81 (95% CI 0.67–4.84)
Syncope is common in patients with ATTR-CM (prevalence 26.6%) but is not an independent predictor of all-cause mortality.
Barge‐Caballero et al. (2022) conducted a cohort in transthyretin amyloid cardiomyopathy (ATTR-CM) (n=128). Syncope vs. No syncope was evaluated on all-cause mortality (HR 1.81, 95% CI 0.67-4.84). In patients with transthyretin amyloid cardiomyopathy, syncope was not independently associated with all-cause mortality after multivariate adjustment (HR 1.81; 95% CI 0.67-4.84).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: